<DOC>
	<DOCNO>NCT00004585</DOCNO>
	<brief_summary>The purpose study see certain combination anti-HIV drug safe effective HIV-infected patient . The drug combination include tablet contain lamivudine zidovudine ( call Combivir ) plus abacavir plus efavirenz .</brief_summary>
	<brief_title>A Study Safety Effectiveness Combination Anti-HIV Therapy HIV-Infected Adults</brief_title>
	<detailed_description>Patients take open-label Combivir plus abacavir plus efavirenz 48 week . [ AS PER AMENDMENT 4/20/00 : Patients take Combivir plus abacavir Week 24 receive triple-nucleoside-combination tablet ( TCT ) ( abacavir/lamivudine/zidovudine ) begin Week 24 continue Week 48 , combination efavirenz ( nevirapine patient make protocol-allowed substitution ) . Patients take Combivir abacavir Week 24 continue study substitute protocol-allowed drug regimen , provide plasma HIV RNA 400 copies/ml 24 week . ] Following enrollment Study Day 1 , on-study evaluation ( virologic safety ) perform Weeks 2 , 4 , 8 , 12 , 16 , every 8 week Week 48 ( end study ) . CD4 evaluation perform baseline Weeks 4 , 8 , every 8 week Week 48 . Immune reconstitution test perform baseline Weeks 12 , 24 , 48 . Patients complete PMAQ7 version 1.1 medication adherence questionnaire Weeks 2 , 8 , 12 , 24 , 48 ( last study visit ) . All patient request return post-study follow-up evaluation 2 4 week last on-study visit . Patients must plasma HIV RNA le 400 copies/ml Week 24 order continue study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have HIV level 50,000 copies/ml within 21 day prior start treatment . Are least 18 year age . Are willing use effective method birth control study . ( This study change . A CD4 cell count 50/mm3 within 21 day prior start treatment longer require . ) Exclusion Criteria Patients eligible study : Are pregnant . Have AIDS . Can take medication mouth . Have hepatitis active . Are enrolled investigational drug study . Are allergic study drug . Have serious medical condition , heart disease . Have ever take certain antiHIV drug nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) protease inhibitor ( PIs ) . Have ever 7 day treatment nucleoside reverse transcriptase inhibitor ( NRTI ) . Patients prior treatment abacavir prior treatment least one following : lamivudine zidovudine . Have radiation therapy chemotherapy within 4 week prior study entry , plan therapy study . Have receive medication might affect immune system , systemic corticosteroid , interleukin , vaccine , interferon within 4 week prior study entry . Have receive HIV vaccine within 3 month prior study entry . Are take foscarnet , hydroxyurea , drug work HIV . Have take certain medication astemizole , cisapride , dihydroergotamine , ergotamine , ganciclovir , interferonalpha , midazolam , terfenadine , triazolam within 21 day study entry . Abuse alcohol drug . Are unable complete whole study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2000</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>abacavir</keyword>
	<keyword>efavirenz</keyword>
</DOC>